Milbar Laboratories' Benzoyl Peroxide Wash Recalled Globally Due to GMP Deviations
Milbar Laboratories, Inc. initiated a Class II recall of 7,591 bottles of DCL B Prox10 Anti-Blemish Wash (Benzoyl Peroxide 10%) due to GMP deviations. This voluntary action, impacting global distribution, underscores critical supply chain and regulatory risks. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar disruptions and ensure product integrity.
FDA Mandated Recall: Milbar Laboratories' GMP Deviations for Benzoyl Peroxide 10% Wash
Milbar Laboratories, Inc., based in East Haven, CT, initiated a voluntary Class II recall (D-0084-2021) for its DCL B Prox10 Anti-Blemish Wash, a product containing Benzoyl Peroxide 10%. This critical action, initiated on October 9, 2020, and officially terminated by the FDA on January 4, 2023, stemmed directly from identified Good Manufacturing Practice (GMP) deviations. For procurement directors, this highlights the paramount importance of supplier adherence to stringent quality control standards; a lapse in GMP can lead to significant product integrity issues, even for seemingly low-risk dermatological formulations. The recall involved 7,591 bottles across three specific lots: MV098-4 (Exp. Dec-21), JW995 (Exp. Sep-22), and Fx381 (Exp. Jun-23). The Class II classification indicates that the product's use or exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. However, for regulatory affairs heads, any deviation from GMP, regardless of the immediate severity classification, signals a fundamental breakdown in quality systems that can erode market trust and invite further regulatory scrutiny. This event underscores that even established firms like Milbar Laboratories must maintain continuous vigilance over their manufacturing processes to prevent costly and reputation-damdamaging recalls.
Global Supply Chain Exposure: Impact of Milbar's Benzoyl Peroxide Product Withdrawal
The distribution pattern of Milbar Laboratories' recalled DCL B Prox10 Anti-Blemish Wash extended throughout the United States, including Puerto Rico, and internationally. This broad reach means that the GMP deviations at Milbar Laboratories had a significant ripple effect across multiple global markets, impacting diverse supply chains. For supply chain VPs, this necessitates a thorough review of all dermatological product sourcing strategies, particularly for over-the-counter (OTC) medications containing active pharmaceutical ingredients like Benzoyl Peroxide. The recall of 7,591 bottles, though not a massive volume in absolute terms, represents a tangible disruption for any downstream formulators, distributors, or retailers relying on these specific lots. Business development executives must consider the potential for brand damage and loss of market share when a key supplier faces such regulatory actions. The international distribution also complicates the recall logistics, requiring coordination with various national regulatory bodies beyond the FDA. This event serves as a stark reminder that a single manufacturing quality issue at one facility can trigger widespread operational challenges, demanding robust contingency planning and multi-jurisdictional compliance management from all partners in the supply chain.
Navigating Regulatory Compliance and Future Sourcing for Dermatological Ingredients
The termination of Milbar Laboratories' recall on January 4, 2023, indicates that the immediate product removal and accountability for the affected lots have been addressed. However, for regulatory affairs heads, the underlying GMP deviations that prompted the recall remain a critical area of focus. The FDA's consistent enforcement of GMP standards, as evidenced by this recall and other recent actions like Essential Wellness Pharma's sterility failure recall, signals an unwavering commitment to product quality and patient safety. Procurement directors sourcing active pharmaceutical ingredients (APIs) or finished drug products, especially for high-volume dermatological applications like Benzoyl Peroxide, must prioritize comprehensive supplier qualification processes that go beyond initial audits. Continuous monitoring of supplier quality systems, including unannounced audits and regular data reviews, is essential to mitigate future risks. This event reinforces the need for robust quality agreements and clear accountability frameworks with contract manufacturers. Diversifying the supplier base for critical ingredients like Benzoyl Peroxide, while challenging, can also reduce reliance on single points of failure, safeguarding against market disruptions caused by regulatory non-compliance.